Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in Nonsense-Mutation-Mediated Cystic Fibrosis
NCT00458341Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ataluren in cystic fibrosis (CF) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoints: Change From Baseline in Total Chloride Transport at Day 14 of Cycles 1 and 2, Number of Participants With a Chloride Transport Response at Day 14 of Cycles 1 and 2 and 1 more. Started Mar 2007; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00458341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458341.